Novartis Wins FDA Nod for Rhapsido in Symptomatic Dermographism

Basel, October 7, 2026 – Novartis announced that the U.S. Food and Drug Administration approved Rhapsido (remibrutinib), an oral, highly selective Bruton's tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism whose symptoms are inadequately controlled by H1 antihistamines. In the Phase III RemIND trial, 29.3% of Rhapsido-treated patients achieved complete hive resolution at Week 12 versus 14.0% on placebo, a statistically significant difference the company reported at p=0.0229. Responses appeared as early as Week 2.

Context — Why This Approval Matters Now

The approval extends Rhapsido beyond chronic spontaneous urticaria (CSU), the indication the FDA cleared just over a year ago, according to the company's own framing of the milestone. Rhapsido is now the only prescription treatment with approved uses in both CSU and SD, the two conditions the company says account for more than 90% of adults with chronic hives.

Symptomatic dermographism is the most prevalent form of chronic inducible urticaria, a category in which everyday skin friction, scratching, or rubbing can trigger hives and itch. The company cites survey work showing more than 50% of patients remain symptomatic despite taking H1 antihistamines, which is the population this label addresses.

The catalyst chain is straightforward. Novartis ran an SD cohort inside the Phase III RemIND study, generated a complete-response endpoint measured by the Total Fric Score, and filed. The FDA cleared the application, converting an investigational use into a labeled one.

What changed for clinicians is the existence of a specifically indicated option. Historically, the company and the trial investigators describe SD care as limited to antihistamines and off-label measures. That gap is the commercial and clinical rationale behind the filing.

The macro backdrop is not the story here. This is a single-asset regulatory event for a large-cap pharmaceutical issuer, and the report gives no revenue guidance, no pricing, and no launch timeline for the SD indication.

Data — What the Numbers Show

The headline figure is the complete-response rate at Week 12: 29.3% on Rhapsido against 14.0% on placebo. That is roughly a doubling of the response rate, and it is the number the FDA reviewed for this cohort.

Endpoint	Rhapsido	Placebo
Complete hive resolution, Week 12	29.3%	14.0%
Statistical significance	p=0.0229	—
First observed response	Week 2	—

Safety data through Week 24 were consistent between the SD and CSU populations, per the company. The most common adverse events at an incidence of 3% or higher were nasopharyngitis, bleeding, headache, nausea, and abdominal pain. The label requires no routine lab monitoring, which the company presents as a practical differentiator.

The report does not disclose SD prevalence in absolute patient numbers, the price of the drug, or any revenue forecast tied to the new indication. Novartis also did not disclose the terms under which it expects reimbursement coverage to develop.

The only peer comparison the company offers is internal: Rhapsido against its own CSU label, where it already holds approval in the U.S., EU, UK, and China. The SD clearance makes the U.S. label broader than the European one, which still covers CSU only.

Analysis — What It Means for Pharma and Biotech

Second-order effects land in two places. First, the BTK-inhibitor class gains a second dermatologic indication in the U.S., which strengthens the commercial case for oral BTK inhibition in immune-mediated disease generally. Novartis said remibrutinib is also being studied in hidradenitis suppurativa and food allergy.

Second, the read-through to the rest of the pipeline matters more than the SD label itself. The company reported positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, citing a clinically meaningful reduction in annualized relapse rates and a delay in disability progression versus teriflunomide, with no liver safety signals. A liver-signal-free profile across indications is the asset's central commercial argument.

The limitation is that SD is a narrow indication. The trial's placebo arm cleared hives in 14.0% of patients, which means the absolute incremental benefit is roughly 15 percentage points. Investors should weigh that against the cost of a specialty oral therapy and any payer friction, neither of which the report quantifies.

Positioning is difficult to read from a press release alone. What the report establishes is that Novartis is submitting the full RemIND dataset to health authorities globally where appropriate, which signals a multi-jurisdiction filing strategy rather than a U.S.-only launch. Investors tracking the healthcare sector can follow regulatory milestones through the Fazen Markets healthcare coverage.

Outlook — What to Watch Next

The near-term catalyst is the global filing sequence. The company said it plans to submit the full RemIND dataset to health authorities globally, and the report gives no dates for those submissions or decisions.

A second catalyst sits in the broader remibrutinib program: the hidradenitis suppurativa and food allergy studies remain ongoing, and the report provides no readout timing. The multiple sclerosis data are already reported as positive topline results, with no filing date disclosed.

The cold urticaria and cholinergic urticaria cohorts inside RemIND are the third thing to watch. The company evaluated remibrutinib in both, but the report stops short of stating whether it will seek labels in those forms of chronic inducible urticaria.

No share price, index level, or yield is attached to this event in the report, so there is no level to watch on the equity. The measurable variables are regulatory: label breadth in Europe, where Rhapsido remains CSU-only, and the pace of the global RemIND submissions. Broader biotech sector moves can be tracked via Fazen Markets indices data.

Frequently Asked Questions

What is symptomatic dermographism and why did it need a new drug?

Symptomatic dermographism is the most prevalent form of chronic inducible urticaria, where skin friction, scratching, or rubbing triggers hives and itch. The company cites data showing more than 50% of patients remain symptomatic despite H1 antihistamines. Before this approval, no therapy carried an FDA label specifically for the condition, so care relied on antihistamines and off-label options.

How does the RemIND trial result compare with the placebo response?

At Week 12, 29.3% of Rhapsido patients achieved complete hive resolution versus 14.0% on placebo, with a p-value of 0.0229. Responses were observed as early as Week 2. The placebo arm's 14.0% clearance rate is the baseline against which the incremental benefit is measured, and the trial used the Total Fric Score as its response measure.

What are the most common side effects of Rhapsido in this population?

Through Week 24, the safety profile in symptomatic dermographism was consistent with the chronic spontaneous urticaria data, according to the company. Adverse events at an incidence of 3% or higher included nasopharyngitis, bleeding, headache, nausea, and abdominal pain. The label requires no routine lab monitoring, which the company highlights as a practical point for prescribers.

Bottom Line

Novartis turned a 29.3% versus 14.0% Week 12 response rate into the first FDA-labeled therapy for symptomatic dermographism.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.